Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Plastic Or Puncture-Resistant Glass Capillary Tubes Recommended By FDA

This article was originally published in The Gray Sheet

Executive Summary

Sales of plastic and mylar-coated glass capillary tubes, which are more costly than traditional plain glass tubes, could receive a boost following a warning by three federal agencies about the potential risks to health care workers from bloodborne diseases.

You may also be interested in...



OSHA Regs Will Not Keep Unsafe Sharps From Workplace - HRG Petition

FDA should remove from the market all blood collection devices and I.V. catheters for which safer alternatives exist, Public Citizen's Health Research Group is urging in a Nov. 29 petition to Commissioner Jane Henney.

Claim That Supplement Boosts Children’s Focus Could Spur FTC Attention

Creekside Natural Therapeutics might hear from the FTC after failing to show in an industry self-regulation forum that it would correct misleading claims for its Focused Mind Jr. supplement promoted as an alternative to ADHD drugs.
UsernamePublicRestriction

Register

MT011406

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel